ArticleAvicenna journal of phytomedicine2026
The effect of cynaropicrin, a sesquiterpene lactone, on the migratory properties of triple-negative breast cancer cells and the underlying mechanisms.
Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cynaropicrin inhibits pancreatic cancer cell viability and disrupts cellular redox homeostasis.microPublication biology · 2026Article
- In Silico and In Vitro Evaluation of δ-cadinene fromCancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Triple-negative breast cancer (TNBC) is the most metastatic type of breast cancer. Cynaropicrin, a sesquiterpene lactone, shows potential anticancer effects. This study evaluated cynaropicrin's impact on metastasis and angiogenesis in TNBC cells. Materials and Methods: MDA-MB-231 and MDA-MB-468 cell lines were exposed to incrementing concentrations of cynaropicrin. The proliferation of the cell lines was assayed using the MTT method. A wound scratch technique was chosen to appraise the migratory properties of cells following cynaropicrin treatment. The transcript levels of epithelial-mesenchymal transition (EMT) and pro-angiogenic factors were quantified via quantitative polymerase chain reaction. The western blotting technique estimated the amount of E-cadherin, N-cadherin, Fibronectin, Vimentin, and VEGFA. Results: The proliferation of MDA-MB-231 and MDA-MB-468 cells was significantly lowered due to cynaropicrin in a concentration-associated way. Results of the wound healing method uncovered that cynaropicrin could mitigate the migration of breast-derived MDA-MB-231 and MDA-MB-468 cells. Cynaropicrin also upregulated E-cadherin and hindered the protein expression of N-cadherin, Vimentin, Fibronectin 1, and VEGFA in breast-derived MDA-MB-468 and MDA-MB-231 cells. Conclusion: The present findings indicated the anti-metastatic capacity of cynaropicrin against TNBC by a mechanism that implicated the inhibition of the EMT and pro-angiogenic factor VEGFA. These outcomes suggest cynaropicrin as an anti-metastatic and anti-angiogenic sesquiterpene lactone against TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.